Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Omacetaxine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Homoharringtonine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Omacetaxine | DRUG | 1.25 mg/m2 subcutaneous twice daily for 14 days |
Inclusion Criteria: * Be ≥18 years old. * Be diagnosed with relapsed or refractory leukemia including chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS) * Relapsed defined as reappearance of leukemic blasts ...
Omacetaxine is an investigational small molecule being studied for the treatment of hematologic tumors, which are cancers of the blood and bone marrow. It is currently in Phase 1 clinical development and has not been approved by the FDA.
Omacetaxine is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker symbol TEVA. The drug is currently in Phase 1 clinical development for hematologic tumors.
Omacetaxine is in Phase 1 clinical development. It is an investigational drug being studied for hematologic tumors and has not been approved by the FDA. One Phase 1 trial has been completed.
Omacetaxine has one completed clinical trial, NCT00675350, a Phase 1 pharmacokinetic study of homoharringtonine (omacetaxine mepesuccinate) administered subcutaneously to patients with advanced solid and hematologic tumors. The trial enrolled 12 participants in the United States.
Yes, Omacetaxine is also known as homoharringtonine and omacetaxine mepesuccinate. The clinical trial NCT00675350 refers to the drug as homoharringtonine (omacetaxine mepesuccinate), confirming these names refer to the same investigational drug.